前往化源商城

2138-33-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4649948
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Data Source: Gates Foundation Compound Collection
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Percent Effect=-0.4113%
Percent Effect=5.918%
Percent Effect=24.74%
Percent Effect=-17.79%
Percent Effect=76.74%
22.7813IC50=22781.31nM
Percent Effect=-1.838%
Percent Effect=13.25%
Percent Effect=8.892%
Percent Effect=-2.138%
Percent Effect=-11.1%
Percent Effect=12.13%
Percent Effect=5.305%
Percent Effect=4.955%
Percent Effect=21.13%
Percent Effect=2.237%
Percent Effect=8.675%
Percent Effect=-6.461%
Percent Effect=-6.594%
Percent Effect=-15.11%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4649949
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Data Source: Gates Foundation Compound Collection
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Percent Effect=-3.24%
Percent Effect=-13.31%
Percent Effect=-14.92%
Percent Effect=19.22%
Percent Effect=0.5922%
Percent Effect=5.491%
Percent Effect=16.44%
Percent Effect=-8.493%
Percent Effect=31.52%
Percent Effect=-34.04%
Percent Effect=15.71%
Percent Effect=7.437%
Percent Effect=1.274%
Percent Effect=47.08%
Percent Effect=-6.198%
Percent Effect=34.07%
Percent Effect=24.8%
Percent Effect=26.03%
Percent Effect=-7.513%
Percent Effect=20.66%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Acinetobacter baumannii
External ID: CHEMBL4296188
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL614425
ChEMBL Target Name: Acinetobacter baumannii
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: CO-ADD Antimicrobial Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
10MIC>10000nMMedian N= 2; Maxinhib 10.4 Pct
20MIC>20000nMMedian N= 2; Maxinhib 10.3 Pct
5MIC=5000nMMedian N= 2
Inhibition=22.02%Average; N=2
10MIC>10000nMMedian N= 2; Maxinhib 7.2 Pct
Inhibition=0.29%Average; N=2
Inhibition=13.44%Average; N=2
Inhibition=15.75%Average; N=2
Inhibition=30.31%Average; N=2
20MIC>20000nMMedian N= 2; Maxinhib 19.9 Pct
10MIC>10000nMMedian N= 2; Maxinhib 13.5 Pct
Inhibition=12.68%Average; N=2
Inhibition=8.04%Average; N=2
Inhibition=21.28%Average; N=2
20MIC>20000nMMedian N= 2; Maxinhib 17.6 Pct
10MIC>10000nMMedian N= 2; Maxinhib 10.9 Pct
20MIC>20000nMMedian N= 2; Maxinhib 24.8 Pct
Inhibition=19.94%Average; N=2
10MIC>10000nMMedian N= 2; Maxinhib 15.2 Pct
Inhibition=19.7%Average; N=2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Pseudomonas aeruginosa
External ID: CHEMBL4296187
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL348
ChEMBL Target Name: Pseudomonas aeruginosa
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: CO-ADD Antimicrobial Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
Inhibition=10.84%Average; N=1
Inhibition=14.55%Average; N=1
Inhibition=-13.46%Average; N=1Outside typical range
Inhibition=21.47%Average; N=2
Inhibition=32.07%Average; N=1
Inhibition=2.27%Average; N=1
Inhibition=-21.74%Average; N=1Outside typical range
Inhibition=9.41%Average; N=1
Inhibition=19.34%Average; N=1
Inhibition=-25.08%Average; N=1Outside typical range
Inhibition=9.21%Average; N=4
Inhibition=15.98%Average; N=4
Inhibition=8.03%Average; N=1
Inhibition=-1.26%Average; N=1
Inhibition=6.81%Average; N=1
Inhibition=-8.48%Average; N=1
Inhibition=25.25%Average; N=1
Inhibition=44.67%Average; N=1
Inhibition=1.69%Average; N=1
Inhibition=2.93%Average; N=1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: LDHA
Protocol: The assay was optimized to 1536-well plates. Briefly, 3 muL of human lactate dehydrogenase 5 (#A38558H, Meridian Life Science, Inc., Memphis, TN) in LDH assay buffer (200 mM Tris HCl pH 7.4, 100 microM EDTA and 0.01% Tween-20) was added to a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of DMSO-solubilized compound (both library and vehicle controls) to each 1536-well assay plate. Following compound transfer, 1 muL of substrate solution containing NADH and sodium pyruvate (Sigma-Aldrich, St. Louis, MO) in LDH assay buffer was dispensed via BioRAPTR FRD to initiate the reaction. Final concentrations in the 4 microL reaction volume were 2 nM LDHA enzyme, 0.06 mM NADH and 0.2 mM sodium pyruvate. Following a 5 minute incubation period at room temperature, 1 muL of detection reagent (C. kluyveri diaphorase (Sigma-Aldrich) and resazurin sodium salt (Sigma-Aldrich) in LDH assay buffer) was added to a total volume of 5 muL. Final concentrations of detection reagents were 0.133 mg/mL diaphorase and 37 muM resazurin. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (ex540, em590 nm) at 0 and 20 minutes. Fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate.
Comment: PubChem score indicates % inhibition at 229 uM or 114 uM of the compound (Max_response). Active compounds with Max_response greater than -100%, PUBCHEM_ACTIVITY_SCORE is 100. Active compounds with Max_response between -80% and -100%, PUBCHEM_ACTIVITY_SCORE is 80. Active compounds with Max_response between -60% and -80%, PUBCHEM_ACTIVITY_SCORE is 60. Active compounds with Max_response between -30% and -60%, PUBCHEM_ACTIVITY_SCORE is 40. Inconclusive Compounds with Max_response between -25% and -30% have PUBCHEM_ACTIVITY_SCORE 20. For all inactive compounds with Max_response greater than -25%, PUBCHEM_ACTIVITY_SCORE is 0
Max_ResponseActivity at 2.29 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMActivity at 229.0 uMCompound QC
-13.2744-14.0597-11.6112-13.2744QC'd by CBC
-13.2736-2.2436-1.4106-3.5076-4.2706-13.2736QC'd by ChemBridge
-13.2725-6.3492-3.253-0.0584-6.7999-13.2725QC'd by Enamine
-13.2721-2.684-6.1454-14.2744-13.2721-0.8973QC'd by InterBioScreen
-13.26881.98380.4889-13.2688QC'd by CBC
-13.2682-4.48462.9589-5.115-5.7595-13.2682QC'd by Sytravon
-13.2658-0.93-4.4888-3.7077-0.7595-13.2658QC'd by Scripps Research Institute Molecular Screening Center-Florida
-13.2621-10.0397-8.5786-8.5671-13.2621-10.4851QC'd by InterBioScreen
-13.2619-4.902-18.7355-13.2619QC'd by CBC
-13.2616-5.6993-9.4488-8.2485-1.1117-13.2616QC'd by Asinex Ltd.
-13.2589-2.6923-5.6679-1.3754-4.9233-13.2589QC'd by ChemBridge
-13.2586-7.6996-6.7417-9.0608-13.258613.0861QC'd by Chem Div
-13.2584.5885-10.8854-13.258QC'd by CBC
-13.2566-1.7741-2.7236-3.5771-3.8709-13.2566QC'd by Chem Div
-13.255-2.1061.9951-5.3796-7.5294-13.255QC'd by Sytravon
-13.2542-3.8713-0.3776-5.8085-5.7762-13.2542QC'd by Sytravon
-13.2537-9.0401-8.2673-9.7055-13.2537QC'd by ChemBridge
-13.2524-8.3625-5.9151-4.3599-2.4204-13.2524QC'd by Life Chemicals
-13.2524-11.5667-8.9808-13.1831-13.2524-13.0056QC'd by Enamine
-13.252412.60356.6367-13.2524QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-FF
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an over night incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.112 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.871 uMActivity at 0.984 uMActivity at 1.439 uMActivity at 2.300 uMActivity at 4.560 uMActivity at 5.230 uMActivity at 7.193 uMActivity at 11.50 uMActivity at 22.87 uMActivity at 26.96 uMActivity at 44.22 uMActivity at 57.50 uMActivity at 114.7 uMActivity at 121.0 uMCompound QC
Inactive0-6.84.95490.81592-8.87640 0 0 0-0.3922-6.984.92071.8774-0.3922QC'd by CBC
Inactive0-64.95490.99893-8.474340 0 0 1-8.9436-8.7286-0.74863.1076-8.9436QC'd by CBC
Inactive0-5.451.75290.999931.5-1.401840 0 0 10-1.16822.48627.83070QC'd by CBC
Inactive0-60.60.9574-3.55781840 0 0 0-2.964813.96745.37522.1822-2.9648QC'd by CBC
Activator0.891355.35450Complete curve; partial efficacy; poor fit-6.054.95490.996847.9876-7.36691.40 0 0 045.9161-7.516336.245149.430745.9161QC'd by CBC
Inactive04-0.40613.15817.14891.8466-0.4061QC'd by CBC
Inactive048.02199.75862.63914.5158.0219QC'd by CBC
Inactive0-4.72.90230.933614-3.767840 0 0 013.2222-6.4732-1.1472-0.694213.2222QC'd by CBC
Inactive0-6.754.95490.62345.5-2.856340 0 0 1-0.8656-1.96369.1142.2001-0.8656QC'd by CBC
Activator3.1623120.58050Partial curve; high efficacy; poor fit-5.52.58841125.84165.26112.30 0 0 1-13.87585.026113.541121.9395-13.8758QC'd by CBC
Inactive0-5.054.0950.99539.916310.540 0 0 039.90711.81019.210332.148439.907QC'd by CBC
Inactive0-6.754.95490.68855.5-14.272340 0 0 0-1.4364-12.310313.15054.6329-1.4364QC'd by CBC
Inactive0-6.84.95490.48777-4.29940 0 0 012.0135-2.33258.02360.561112.0135QC'd by CBC
Activator14.125456.99660Partial curve; partial efficacy; poor fit-4.851.55790.997555.2294-1.76712.40 0 0 049.6994-2.53631.145221.508449.6994QC'd by CBC
Inactive0-6.74.95490.69788.5-0.540 0 0 10.95120.101311.40645.14890.9512QC'd by CBC
Inactive0-6.84.95490.67113-7.754240 0 0 10-4.378520.24456.04850QC'd by CBC
Inactive04-3.0754-7.5861-4.61-0.5732-3.0754QC'd by CBC
Inactive0-4.950.70.969-220.540 0 0 02.43720.237815.432810.70092.437QC'd by CBC
Inactive0-6.84.50450.7622-2-15.31340 0 0 0-4.8971-12.76082.2051-3.2116-4.8971QC'd by CBC
Inactive0-6.054.50450.999713-6.546540 0 0 10-6.28888.282512.94060QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24983 靶标:Huntingtin
External ID: KUHTS-Muma KU-CaM-Htt INH-01
Protocol: 1; Dispense 45 nl compounds (10 mM stocks) using ECHO 555 to Alpha 384 well assay plates. Dispense 45 nl DMSO to control columns 1 and 2 of 384 well plates.
2; Incubate 5 ul of 6XHis-mHTT (Final, 13 nM) with the compounds for 40 mins at room temperature in buffer containing 10 mM Tris.HCl pH 7.4, 1 mM calcium chloride, 150 mM sodium chloride, 0.1% BSA and 20% glycerol.
3; Dispense 5 ul of 6XGST-CaM (Final 13 nM) in buffer A.
4; Incubation; 1 hour (dark at 25C)
5; Dispense 20 ul of Nickel chelate acceptor beads (Final, 20 ugs/ml) and Glutathione donor beads (Final, 30 ugs/ml). Incubate for 2h, room temperature.
6; Detector: Perkin Elmer Enspire, Alphascreen Module (Excitation 680nm/Emission 570nm).

NOTES (numbers refer to Sequence numbers above)
1. Alphascreen bead incubations were performed in green light, TiterTek setting 400rpm.
2. All incubation and addition steps were followed by mixing and centrifugation at 400g,1 min.
3. The percent inhibition for each compound was calculated as follows:
100- [100 *((Test Compound-Median Low Control) / (Median High Control - Median Low Control))]

Where:
Test_Compound is defined as wells containing His mHTT + GST CaM in the presence of test compound

High_Control is defined as wells containing His mHTT + GST CaM and DMSO.

Low_Control is defined as wells containing His mHTT and DMSO.
Comment: All percent inhibition data reported were normalized to high and low controls on a per-plate basis. The results of primary screening data include compounds contributing to assay signal interference, interference with tags binding to Alpha beads, chelators, process related artifacts etc.. The actives were defined as compounds that inhibited Alphascreen reads to greater than 50%.
Activity at 15 uMPhenotype
-3.1
4.2
-4.8
-0.6
-3.9
-6
75.3Inhibitor
-10.3
-7
-2
-3.8
17.6
-4.8
-4.1
-7.8
-7.5
15.2
7.8
-2.5
-13.4
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-Ren
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an overnight incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.092 uMActivity at 0.115 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.911 uMActivity at 1.057 uMActivity at 1.771 uMActivity at 2.301 uMActivity at 4.634 uMActivity at 5.773 uMActivity at 11.50 uMActivity at 16.40 uMActivity at 23.82 uMActivity at 35.99 uMActivity at 57.50 uMActivity at 114.4 uMActivity at 129.1 uMActivity at 273.4 uMActivity at 288.0 uMCompound QC
Activator15.848972.76670Partial curve; partial efficacy; poor fit-4.810.995671.5604-1.20632.40 0 0 056.9219-2.70325.718429.072156.9219QC'd by CBC
Inactive0-5.652.72020.876-3.076-11.137840 0 0 0-4.8556-10.9482-10.07-0.8967-4.8556QC'd by CBC
Activator14.1254116.35980Partial curve; high efficacy; poor fit-4.852.25260.9976114.9836-1.37612.30 0 0 0110.7742-4.01652.526342.9951110.7742QC'd by CBC
Inactive0-4.354.95490.62039-2.125740 0 0 06.649-3.82222.8199-4.68816.649QC'd by CBC
Activator22.387269.80210Partial curve; partial efficacy-4.651.75290.99966.6142-3.18792.20 0 0 055.5041-3.9302-1.545313.513455.5041QC'd by CBC
Inactive04-10.8628-6.0946-6.3923-2.7723-10.8628QC'd by CBC
Activator3.162346.56160Complete curve; partial efficacy-5.51140.0835-6.47811.20 0 0 037.587-4.78416.055430.206537.587QC'd by CBC
Inactive04-5.1322-4.7917-1.3649-10.6528-5.1322QC'd by CBC
Inactive0-4.44.44950.7339130.999240 0 0 011.2209-2.50075.02590.301511.2209QC'd by CBC
Inactive0411.75236.54273.70753.760211.7523QC'd by CBC
Inactive04-13.953-10.1902-10-18.4577-13.953QC'd by CBC
Inactive04-4.5083-2.06295.4547-1.4612-4.5083QC'd by CBC
Inactive04-7.5306-15.4441-6.4413-15.0974-7.5306QC'd by CBC
Inactive0-4.652.25260.9477-26.3385-15.893440 0 0 0-25.2821-17.3753-14.9112-17.8522-25.2821QC'd by CBC
Inactive04-12.6647-11.4457-10.7961-20.5075-12.6647QC'd by CBC
Inactive0-5.14.95490.594-16.1597-5.606740 0 0 1-3.9011-10.3012-3.0056-14.7164-3.9011QC'd by CBC
Inactive0-5.154.95490.9234-15.5602-3.948840 0 0 1-5.8836-5.9172-2.4573-14.6335-5.8836QC'd by CBC
Inactive0-4.354.44950.7251-13.3612-240 0 0 0-10.7177-1.1966-5.59780.8791-10.7177QC'd by CBC
Inactive0-5.74.50450.80751.010810.540 0 0 04.435110.69059.7726-1.65774.4351QC'd by CBC
Activator35.481330.78070Partial curve; partial efficacy; poor fit-4.451.47810.970347.280716.52.40 0 0 037.296914.420618.816221.266337.2969QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Pseudomonas aeruginosa
External ID: CHEMBL4296802
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL348
ChEMBL Target Name: Pseudomonas aeruginosa
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: CO-ADD Antimicrobial Screening
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsActivity CommentData Validity Comment
Inhibition=-33.42%Average; N=1Outside typical range
Inhibition=1.44%Average; N=1
Inhibition=-11.05%Average; N=1Outside typical range
Inhibition=19.22%Average; N=1
Inhibition=-31.54%Average; N=1Outside typical range
Inhibition=-12.91%Average; N=1Outside typical range
Inhibition=12.18%Average; N=1
Inhibition=-14.83%Average; N=1Outside typical range
Inhibition=17.54%Average; N=1
Inhibition=-38.58%Average; N=1Outside typical range
Inhibition=-10.22%Average; N=1Outside typical range
Inhibition=14%Average; N=1
Inhibition=1.67%Average; N=1
Inhibition=14.76%Average; N=1
Inhibition=-28.2%Average; N=1Outside typical range
Inhibition=13.08%Average; N=1
Inhibition=3.75%Average; N=1
Inhibition=10.88%Average; N=1
Inhibition=-0.78%Average; N=1
Inhibition=-7.12%Average; N=1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NIAID 靶标:N/A
External ID: HIV Cellular Data
Protocol: N/A
Comment: N/A
SpeciesStrainIsPseudotypeVirusAssayMethCellTypeCellType2TargetMutationsEC50ModEC50EC50UnitECOtherPctECOtherPctUnitECOtherConcECOtherConcUnitToxAssayMethToxCellTypeCC50ModCC50CC50UnitTIModTIRelResFoldChgCommentsReferenceCitationOther Information
HIV-1LAIRTHuT TK+HuT 78Reverse transcriptase<1uM100%1uMMTT>10uM>10HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
HIV-1MNRTHuT TK+HuT 78Reverse transcriptase<0.3uM76.74%0.3uMMTT>10uM>33.3HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
HIV-1MNRTHuT TK+HuT 78Reverse transcriptase<0.3uM69%0.3uMMTT>10uM>33.3HuT TK+=HuT 78 CELLS EXPRESSING HSV-1 THYMIDINE KINASE; MEASUREMENT WAS MADE ON DAY14 POSTINFECTION AT 100 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.
R5; CLINICAL ISOLATE1(JSL)P24PBMCReverse transcriptaseMDR0.07uM90%1uMMTT>100uM>1428HIV-1(JSL) WAS ISOLATED FROM PATIENTS WHO RECEIVED ANTIRETROVIRAL THERAPY FOR A LONG PERIOD AND WHOSE VIRUS ACQUIRED A NUMBER OF MUTATIONS IN THE RT- AND PR-ENCODING GENES; DETAILS OF MUTATIONS NOT GIVEN15280474SPIRODIKETOPIPERAZINE-BASED CCR5 INHIBITOR WHICH PRESERVES CC-CHEMOKINE/CCR5 INTERACTIONS AND EXERTS POTENT ACTIVITY AGAINST R5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN VITRO. Journal of Virology 2004, 78(16), 8654-8662.ECOtherConcMod:>
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 3 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:6 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 5 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:7 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1NL4-3LUCIFERASE1G5 TReverse transcriptase<1uM99%1uMTRYPAN BLUE>1uM>1ASSAY WAS CONDUCTED ON DAY 7 POST-INFECTION16725040INHIBITION OF HIGHLY PRODUCTIVE HIV-1 INFECTION IN T CELLS, PRIMARY HUMAN MACROPHAGES, MICROGLIA, AND ASTROCYTES BY SARGASSUM FUSIFORME. AIDS Research and Therapy 2006, 3(1), 15 PP.CCOtherPct:3 | CCOtherPctUnit:% | CCOtherConc:1 | CCOtherConcUnit:uM
HIV-1LAVRTU1(THF-.alpha. STIM)U1Tumor necrosis factor alpha~30ug/mL70%50ug/mL>50ug/mL>1.66CHRONICALLY HIV-1 INFECTED PROMONOCYTE CELL LINE8327469THALIDOMIDE INHIBITS THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1. Proceedings of the National Academy of Sciences of the United States of America 1993, 90, 5974-5978.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:50 | CCOtherConcUnit:ug/mL
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM75%10uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM38%2uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1BaLP24 (DAY 18)MACROPHAGES(GM-CSF)MacrophageRibonucleotide reductase<10uM99%50uM>1000uM>10MAXIMAL P24 EXPRESSION AT DAY 187973634HYDROXYUREA AS AN INHIBITOR OF HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 REPLICATION. Science 1994, 266(5186), 801-805.ECOtherPctMod:> | CCOtherPct:0 | CCOtherPctUnit:% | CCOtherConc:1000 | CCOtherConcUnit:uM
HIV-1IIIBRTHT4(R116; AZT RESISTANT CELLS)HT4Reverse transcriptase~0.01uM70%0.01uM~`1uM~100FLOXURIDINE APPEARS TO POTENTIATE AZT ACTIVITY AND ALSO HAVE SOME ANTI-HIV ACTIVITY IN AZT RESISTANT CELL LINES8827211USE OF FLOXURIDINE TO MODULATE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. AIDS Research and Human Retroviruses 1996, 12(11), 965-968.ECOtherPctMod:~ | CCOtherPct:35 | CCOtherPctUnit:% | CCOtherConc:.1 | CCOtherConcUnit:uM
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.1uM52%0.1uMTRYPAN BLUE>100uM>1000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.01uM78%0.01uMTRYPAN BLUE>100uM>10000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-1IIIBSYNCYT FORMMOLT-4/H9(HIV-1(IIIB))MOLT-4gp120<1uM95%10uM-10010uM>10CHRONICALLY INFECTED H9 CELLS9343823TRIAZINE DYES INHIBIT HIV-1 ENTRY BY BINDING TO ENVELOPE GLYCOPROTEINS. Microbiology and Immunology 1997, 41(9), 717-724.CCOtherPct:30 | CCOtherPctUnit:% | CCOtherConc:10 | CCOtherConcUnit:uM
HIV-11.beta.GAL AS A MEASURE OF TAT-MEDIATED TRANSACTIVATIONHeLa H12(HIV-1 LTR-Laz, TAT)HeLaTat:TAR/LTR<0.01uM75%0.01uMTRYPAN BLUE>100uM>10000DRUG AND RECOMBINANT TAT WERE INTRODUCED INTO CELLS THROUGH ELECTROPORATION9561563CURCUMIN AND CURCUMIN DERIVATIVES INHIBIT TAT-MEDIATED TRANSACTIVATION OF TYPE 1 HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT. Research in Virology 1998, 149(1), 43-52.
HIV-11P24MT-4Integrase<0.25uM95%0.25uMMICROSCOPIC EXAMINATION>20uM>80IN THE PRESENCE OF 50% NHS16554152A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904.ECOtherPctMod:>
HIV-11P24MT-4Integrase<0.103uM95%0.103uMMICROSCOPIC EXAMINATION>20uM>194IN THE PRESENCE OF 10% FBS16554152A SERIES OF 5-AMINOSUBSTITUTED 4-FLUOROBENZYL-8-HYDROXY-[1,6]NAPHTHYRIDINE-7-CARBOXAMIDE HIV-1 INTEGRASE INHIBITORS. Bioorganic & Medical Chemistry Letters 2006, 16(11), 2900-2904.ECOtherPctMod:>
HIV-1NL4-3RTMT-4Reverse transcriptase<1uM100%1uMWST-8>1uM>1MEASUREMENTS WERE MADE ON DAY 4, 6 AND 8 POST INFECTION15371436POLYARGININE INHIBITS GP160 PROCESSING BY FURIN AND SUPPRESSES PRODUCTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 INFECTION. The Journal of Biological Chemistry 2004, 279(47), 49055-49063.
HIV-1LAIRTHuT 78Reverse transcriptase<1uM57.14%1uMMTT>10uM>10MEASUREMENT WAS MADE ON DAY10 POSTINFECTION AT 10 TCID509281520USE OF HERPES SIMPLEX VIRUS THYMIDINE KINASE TO IMPROVE THE ANTIVIRAL ACTIVITY OF ZIDOVUDINE. Virology 1997, 235, 398-405.